Clincosm LogoSign in Get a demo

b cell malignancies

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Louisville, Kentucky
  • +6 more
Nov 14, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/79b T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022

Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) Trial in Durham (WT1

Terminated
  • Acute Myelogenous Leukemia (AML)
  • +4 more
  • WT1 derived peptides
  • Durham, North Carolina
    Duke Comprehensive Cancer Center
Dec 7, 2013